DJIA 17,156.85 24.88 0.15%
NASDAQ 4,562.19 9.43 0.21%
S&P 500 2,001.57 2.59 0.13%
market minute promo

Seattle Genetics (NASDAQ: SGEN)



company name or ticker

UPDATE: Bank Of America Upgrades Seattle Genetics

UPDATE: Bank of America Upgrades Seattle Genetics On Trial Risks

Analysts' Actions: APC KBR SGEN TGT VLO

Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog

Seattle Genetics (SGEN) Is Today's Dead Cat Bounce Stock

Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today

Stocks generally disappointed investors on Friday as the Ukrainian situation trumped strong jobs data, but these three stocks performed much worse than the broader market. Find out why.

Why Seattle Genetics, Inc. Shares Soured

Seattle Genetics shares sink despite topping Wall Street's expectations in the first quarter. See what has investors up in arms and what you should do about it.

Seattle Genetics Management Discusses Q1 2014 Results - Earnings Call Transcript

Seattle Genetics' Revenue Rises 19% on Adcetris Sales Growth

Antibody-drug conjugate developer Seattle Genetics delivers strong sales gains from lead drug Adcetris despite a flat year-over-year net loss.

Seattle Genetics, Inc. Discusses Q1 2014 Results (Webcast)

See More Articles...